Salute e Benessere

EssilorLuxottica: Q3/9M 2025 Revenue - Revenue up 11.7% in the third quarter…

Revenue up 11.7% in the third quarterBest quarterly performance ever for the GroupGroup’s revenue +11.7% in the third quarter at constant exchange rates 1, +8.8% in the nine monthsWearables major boost, enlarging the portfolio with a strong pipeline of product innovationVision care and sunglasses growing 5% at constant exchange rates 1and perimeterNorth America and EMEA up double digits in both PS and DTC channelsStellest supported by strong clinical results,...
Nasdaq GlobeNewswire
16/10/2025

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II…

Leuven, BELGIUM – October 16, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on October 15, 2025, from Atlas Special Opportunities II…
Actusnews Wire
16/10/2025

Press release: NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A…

NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEMGhent, Belgium, 16 October 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that, as a result of a subscription to new shares by GEM Global Yield LLC SCS (" GEM…
Nasdaq GlobeNewswire
16/10/2025

Hagar hf: Financial results for Q2 2025/26

Strong performance and a new retail center in the Faroe Islands The interim financial statements of Hagar hf. for the second quarter of the 2025/26 financial year were approved by the company’s Board of Directors and CEO at a board meeting held on 16 October 2025. The statements cover the period from 1 March to 31 August 2025. The interim financial statements include the consolidated accounts of the company and its subsidiaries and have been prepared in accordance with International...
Nasdaq GlobeNewswire
16/10/2025

VIRBAC Announces Third Quarter 2025 Sales

Sustained revenue growth at the end of September of +7.8% at constant exchange rates and scopeUpgrade of the full-year revenue guidance Revenue growth now expected to be between 5.5% and 7.5% at constant rates and scopeAdjusted recurring operating income¹ expected around 16% Press release on October 16, 2025, after market close at 5:45 p.m. CESTKEY FIGURESRevenue in first half of 2025 €1102.4MGrowth at constant exchange ratesand scope 2...
Nasdaq GlobeNewswire
16/10/2025

Wingderm®'s Mesoskin Marks New Milestone in Non-Invasive Delivery with 1.1…

Prof. Hang Wang, Executive Chairman of AMWC China, observed the use of Mesoskin in professional settings. She noted that Mesoskin assists with the application of high-molecular-weight cosmetic ingredients in a gradual and controlled manner. Unlike directly applying products or using tools such as a derma pen, Mesoskin's cartridge tip is designed to cover a larger area, helping beauticians apply cosmetic products efficiently while maintaining a comfortable experience. With its non-invasive design…
PR Newswire
16/10/2025

A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy…

The partnership will initially focus on launching the liquid biopsy application, MSK-ACCESS® powered with SOPHiA DDMTM. This innovative liquid biopsy test is designed to detect actionable genomic alterations from a single blood draw, leveraging state-of-the-art AI to analyze circulating tumor DNA (ctDNA) in a minimally invasive manner. The test utilizes a matched tumor-normal approach which improves accuracy and avoids false positives. By launching the test locally and analyzing samples…
PR Newswire
16/10/2025

Natural Dyes Market to Reach $2.6 Billion, Globally, by 2034 at 6% CAGR: Allied…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A325663 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A325663 Prime determinants of growth The natural dyes market is experiencing robust growth, driven by increasing consumer demand for eco-friendly and sustainable products. Heightened awareness of the environmental and health hazards associated with synthetic dyes—such as water...
PR Newswire
16/10/2025

Infection Control Market worth $77.67 billion by 2030 with 6.3% CAGR |…

Browse in-depth TOC on "Infection Control Market" Browse in-depth TOC on "Infection Control Market" 635 - Tables59 - Figures616 - Pages By treatment,the infection control market is divided into five main segments based on treatment: sterilization products & services, cleaning & disinfection products, protective barriers, endoscope reprocessing products, and other infection control products. Cleaning and disinfection products are crucial in infection control as...
PR Newswire
16/10/2025

Hormonal Contraceptive Market to Reach $26.6 billion, Globally, by 2035 at 3.6%…

Request Sample of the Report on Global Hormonal Contraceptive Market 2035 - https://www.alliedmarketresearch.com/request-sample/4574 Request Sample of the Report on Global Hormonal Contraceptive Market 2035 -https://www.alliedmarketresearch.com/request-sample/4574 Prime determinants of growth The growth of the hormonal contraceptives market is driven by rise in prevalence of unintended pregnancies, increase in awareness of family planning, and government initiatives promoting...
PR Newswire
16/10/2025

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), TO SHARE…

To that end, Vance Thompson, MD, Kayla Karpuk, OD, and Mark Packer, MD, have been invited as collaborating authors for a "Critical Perspectives" article on lacrimal occlusion in the setting of cataract and refractive surgery, which will appear in an upcoming issue of Expert Review of Ophthalmology. Lead author Vance Thompson notes that "Dry eye disease can influence preoperative planning, surgical outcomes, postoperative recovery, satisfaction, and quality of life in patients…
PR Newswire
16/10/2025

OpenEvidence and Veeva Announce Open Vista Partnership

"We are very excited about our long-term partnership with OpenEvidence as we enter the AI chapter in life sciences," said Veeva CEO Peter Gassner. "Combining the strengths of Veeva and OpenEvidence, we can use AI to bridge life sciences companies making life-saving medicines, patients, and the physicians who treat them. With Open Vista our aim is to help life sciences companies accelerate the development of effective new treatments, enable more patients to participate in clinical…
PR Newswire
16/10/2025

Seminal new study on the role of circulating tumour-cell clusters in end-of-life…

Detailed work by Prof. Aceto and others over the past decade has shown that CTC clusters have a much higher propensity to form metastases compared to single CTCs. Building on this, the present study published in Nature Medicine (link) is groundbreaking in uncovering a link between the increased number and size of CTC clusters and vascular occlusions, strongly suggestive of vascular failure as a cause of death in cancer patients. Detailed work by Prof. Aceto and others over the past decade has...
PR Newswire
16/10/2025

Genomics launches Mystra: the world's first and original AI-enabled human…

The pharmaceutical industry faces a significant research and development (R&D) productivity crisis, with the failure rate for drug candidates in clinical trials soaring to 95%. This rate pushes the average cost of bringing a new medicine to market beyond $2.3 billion, leading to unsustainable pricing and restricted patient access to life-saving treatments. Genomics is addressing this challenge by equipping researchers with a powerful solution built on the fact that targets with human genetic…
PR Newswire
16/10/2025

OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, Oct.16, 2025(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has...
Nasdaq GlobeNewswire
16/10/2025

Precision BioLogic Acquires George King Bio-Medical

Kathryn Blasco, CEO and President of George King Bio-Medical and daughter of George King, the company's founder, agrees. "Joining forces with Precision BioLogic enables us to continue our legacy of compassion and innovation. The future looks promising for us and our customers." Kathryn Blasco, CEO and President of George King Bio-Medical and daughter ofGeorge King, the company's founder, agrees. "Joining forces with Precision BioLogic enables us to continue our legacy of…
PR Newswire
16/10/2025

Microban International Appoints Shermon McMillan as New President

As president, McMillan will focus on building the Microban brand and growing the company's reputation as the most trusted name in product protection. His leadership will put customers at the center, prioritize the execution of relevant innovation, and build brand equity. By combining customer centrality, innovation and brand building, McMillan will ensure Microban continues to deliver value for both industry partners and end-users. As president, McMillan will focus on building the Microban...
PR Newswire
16/10/2025

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million…

In consideration for the immediate exercise in full of the Existing Warrants, the investors will receive, in a private placement, new unregistered warrants to purchase up to an aggregate of 14,720,920 of common stock shares (the “New Warrants”). The New Warrants will have an exercise price of $0.54 per share and, will be initially exercisable on the date that stockholder approval of the exercise of the New Warrants is obtained (the “Approval Date”) and will expire five (5) years following...
Nasdaq GlobeNewswire
16/10/2025

Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cosmos Health Inc. ("Cosmos Health" or the “Company”)(NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that on October 15, 2025, it received written notice (the ”Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Listing Rule”).In the Notice, Nasdaq stated that for the last 18 consecutive...
Nasdaq GlobeNewswire
16/10/2025

Zenos Wellness Summit Announces Transformative Keynote Lineup and Strategic…

Featured panel discussions include: Featured panel discussions include: Programming extends beyond keynotes to include morning yoga withLana Nazer, breathwork workshops by Arc ofSweden, a guided sunset walk through historic Diriyah by SANCTUM, and a signature Blue Lotus Ceremony by Bayan Abuzinada featuring adaptogenic elixirs and Yoga Nidra. Throughout the event, JEZALA Wellness will host a recovery lounge with infrared saunas, compression therapy, PEMF massage beds, and red light...
PR Newswire
16/10/2025

The 7iE Smart Matter WiFi Thermostat by Warmup

The First Underfloor Heating Controller with Matter Compatibility The First Underfloor Heating Controller with Matter Compatibility The 7iE Smart Matter WiFi Thermostat is Warmup's most advanced underfloor heating controller ever. Combining premium materials with market-leading automation innovation, the 7iE features Matter technology to ensure effortlessly integration with all major Smart home devices, including Apple Home, Google Home, and Amazon Alexa. Smarter Technology,...
PR Newswire
16/10/2025

Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value…

Event features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALLNEW YORK, Oct.16, 2025(GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today hosts a R&D Day in New York City. The Company’s leadership team and key opinion leaders will present the full Phase 1 dataset and outline...
Nasdaq GlobeNewswire
16/10/2025

C-Path's Disease Modeling Coalition Begins Global Pediatric IBD Work from…

CP-DMC is being established with Quinten Health as the founding AI and disease modeling partner, working alongside both C-Path's Quantitative Medicine Program and Data Collaboration Center to integrate clinical trial and real-world data at scale for model development and application. CP-DMC is being established withQuinten Health as the founding AI and disease modeling partner, working alongside both C-Path's Quantitative Medicine Program and Data Collaboration Center to integrate clinical...
PR Newswire
16/10/2025

SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent…

"Digital twin technology enables integrative visualization of multimodal oncologic data, revealing latent correlations across modalities. By simulating disease trajectories and therapeutic responses within a virtual environment, Digital Twins offer a framework for in silico experimentation, supporting anticipatory and individualized clinical decision-making," said Dr. Pierre Heudel, Medical Oncologist, Centre Léon Bérard. "Digital twin technology enables integrative visualization…
PR Newswire
16/10/2025
Altri  Comunicati